<DOC>
	<DOCNO>NCT01462175</DOCNO>
	<brief_summary>This multicenter , open label , dose-escalating study evaluate safety , pharmacokinetics , pharmacodynamics , efficacy RO5503781 , administer daily ( QD ) weekly ( QW ) participant advanced malignancy except leukemia . Participants receive multiple escalate oral dos two different dose schedule ( Sch ) disease progression unacceptable toxicity occur .</brief_summary>
	<brief_title>A First-In-Human Study RO5503781 Participants With Advanced Malignancies Except Leukemia</brief_title>
	<detailed_description />
	<criteria>Histologically cytologically confirm advanced malignancy , except form leukemia , standard curative palliative measure exist , longer effective , acceptable participant Measurable disease ( accord RECIST Cheson criterion ) evaluable disease prior administration study drug Minimum weight 35 kg life expectancy great equal ( &gt; = ) 12 week Eastern Cooperative Oncology Group ( ECOG ) performance status 0 1 Acute toxicity prior antitumor therapy , surgery , radiotherapy must resolve NCTCTCAE Grade less equal ( &lt; = ) 1 Adequate renal , hepatic bone marrow function Participants stable Central Nervous System ( CNS ) metastasis chronic , stable rate control atrial fibrillation Participants consideration biomarker cohorts apoptosis image cohort must consent able undergo pair biopsy tumor biomarker analyse Able participate willing give write informed consent comply study restriction History form leukemia except Stage 0 1 chronic lymphocytic leukemia ( CLL ) require treatment addition underlie solid tumor Use hormonal therapy within 2 week use investigational agent receive investigational drug &lt; = 4 week prior study treatment start History seizure disorder unstable CNS metastasis Severe and/or uncontrolled cardiovascular disease disorder Active ( acute chronic ) uncontrolled infection Pregnant breastfeed woman HIVpositive participant currently receive antiretroviral treatment Known coagulopathy , platelet disorder history nondrug induce thrombocytopenia Participants receive oral parenteral anticoagulants/antiplatelet agent ; anticoagulant flush maintenance indwell catheter allow Participants know bone marrow disorder may interfere bone marrow recovery Participants hypersensitivity reaction 18Fluorothymidine ( FLT 18F ) compound</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>November 2016</verification_date>
</DOC>